Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab mechanism and efficacy markers in chronic spontaneous urticaria
NL-OMON43836Phase 4Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of omalizumab in chronic idiopathic urticaria (CIU), sponsored by University Medical Center Utrecht. Primary endpoint: Reduction of inflammatory characteristics in skin and blood. Started Jul 2015; status: active, not recruiting.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NL-OMON43836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43836.